Human H1 receptor (HRH1) gene polymorphism is associated with the severity of side effects after desloratadine treatment in Chinese patients with chronic spontaneous uticaria
Human H1 receptor (HRH1) gene polymorphism is associated with the severity of side effects after desloratadine treatment in Chinese patients with chronic spontaneous uticaria
复制标题
人类H1受体（HRH1）基因多态性与中国慢性自发性荨麻疹患者地氯雷他定治疗后副作用的严重程度相关
DOI：
10.1038/s41397-019-0094-0
复制
发表时间：
2020-02-01
影响因子：
2.8
通讯作者：
Chen, Xiang
中科院分区：
文献类型：
--
作者：
Li, Juan;Chen, Wangqing;Chen, Xiang
H1非镇静抗组胺药，如地氯雷他定，是慢性自发性荨麻疹（CSU）的一线治疗选择。然而，地氯雷他定在CSU患者中引起不同程度的镇静副作用，目前还没有生物标志物来预测这种副作用的严重程度。在此，我们评估了HRH 1基因rs 901865多态性与CSU患者地氯雷他定治疗后镇静副作用严重程度之间的关系。114例患者中20例（17.50%）出现镇静副作用，3例（2.63%）出现严重嗜睡。HRH 1 rs 901865 G等位基因频率在经历镇静的患者中显著高于rs 901865 A等位基因的患者（p= 0.0009）。此外，具有rs 901865 G/G基因型的患者比具有rs 901865 G/A基因型的患者遭受更严重的镇静副作用（p= 0.005）。这些结果提供了HRH 1 rs 901865 G/G多态性与地氯雷他定治疗后严重镇静副作用相关的证据。因此，HRH 1 rs 901865等位基因可能作为一个生物标志物，用于预测患有CSU并接受地氯雷他定治疗的患者的镇静副作用的严重程度。
H1 nonsedating antihistamines, such as desloratadine, are first-line treatment options for chronic spontaneous urticaria (CSU). However, desloratadine induces various degrees of sedation side effect in CSU patients, and no biomarkers currently exist for predicting the severity of such side effect. Herein, we evaluated the association betweenHRH1gene rs901865 polymorphism and the severity of sedation side effect following desloratadine therapy in patients with CSU. We found that 20 of the 114 patients (17.50%) showed sedation side effect after desloratadine treatment, and 3 patients (2.63%) experienced serious sleepiness. The frequency ofHRH1rs901865 G allele was significantly higher in patients who experienced sedation than in patients with rs901865 A allele (p= 0.0009). Moreover, patients with the rs901865 G/G genotype suffered a more serious sedation side effect than patients with the rs901865 G/A genotype (p= 0.005). These results provide evidence that theHRH1rs901865 G/G polymorphism is associated with severe sedation side effect after desloratadine treatment. Thus, theHRH1rs901865 allele may potentially be used as a biomarker for predicting the severity of sedation side effect in patients suffering from CSU and treated with desloratadine.